Chronic Constipation
Chronic constipation affects approximately 15% of adults worldwide and is among the most common reasons for outpatient gastrointestinal and pelvic floor referral, with substantial effects on quality of life, healthcare utilization, and direct and indirect cost.[1][2] Symptoms extend beyond infrequent defecation to include straining, sensation of incomplete evacuation, anorectal blockage, and the need for manual maneuvers. For the reconstructive pelvic surgeon, chronic constipation sits at the crossroads of gastroenterology and pelvic floor medicine — it coexists with pelvic organ prolapse, obstructed defecation, and fecal incontinence, and its recognition and treatment are frequently prerequisite to successful pelvic reconstruction.
Epidemiology
- Prevalence: ~14–15% of adults globally; higher in women (~2:1 female-to-male), older adults, and lower-socioeconomic populations.[2]
- Age: Prevalence rises steadily after age 60, with the highest burden in adults >80 years.[2]
- Healthcare utilization: >8 million annual outpatient visits in the United States; a leading driver of GI-related prescription spending.[1]
- Overlap: Roughly one-third of patients with chronic constipation meet criteria for IBS with constipation (IBS-C); a similar proportion have a definable defecatory disorder on physiologic testing.[1][6]
Classification
Chronic constipation is first partitioned into primary (functional) and secondary forms. Primary constipation is further subdivided by pathophysiology.
| Category | Subtype | Defining features |
|---|---|---|
| Primary (functional) | Normal-transit constipation (NTC) | Normal colonic transit; symptom-based; most common subtype |
| Slow-transit constipation (STC) | Delayed colonic transit on scintigraphy or radiopaque markers; reduced high-amplitude propagating contractions | |
| Defecatory (evacuation) disorders | Impaired rectal evacuation from dyssynergia, inadequate propulsion, or structural outlet obstruction. See the dedicated article for physiologic diagnosis (ARM + BET + defecography), biofeedback as first-line, botulinum toxin, and structural surgery. | |
| Secondary | Medications | Opioids, anticholinergics, calcium-channel blockers, iron, calcium, 5-HT3 antagonists, antipsychotics |
| Metabolic / endocrine | Hypothyroidism, hypercalcemia, hypokalemia, diabetes, pregnancy | |
| Neurologic | Parkinson disease, multiple sclerosis, spinal cord injury, autonomic neuropathy | |
| Structural / anatomic | Colorectal cancer, strictures, anal stenosis, large rectocele, full-thickness intussusception |
Diagnosis
Rome IV — Functional Constipation
Diagnosis of functional constipation requires symptoms for the last 3 months with onset at least 6 months prior, and the presence of ≥2 of the following:[3]
- Straining during >25% of defecations
- Lumpy or hard stools (Bristol 1–2) in >25% of defecations
- Sensation of incomplete evacuation in >25% of defecations
- Sensation of anorectal obstruction or blockage in >25% of defecations
- Manual maneuvers to facilitate >25% of defecations (digital evacuation, splinting of the pelvic floor or posterior vaginal wall)
- Fewer than three spontaneous bowel movements per week
Plus:
- Loose stools are rarely present without the use of laxatives
- Insufficient criteria for IBS
Initial Evaluation
A focused history should characterize stool frequency, stool form (Bristol Stool Form Scale), straining, sense of incomplete evacuation, manual maneuvers, duration, and triggers; and should review alarm features: hematochezia, unintentional weight loss, iron-deficiency anemia, new-onset constipation >50 years, rapid progression, or first-degree family history of colorectal cancer or inflammatory bowel disease.[1][5]
A medication review is mandatory — iatrogenic constipation is the most common secondary cause.
Physical examination includes abdominal exam and a digital rectal examination with dynamic maneuvers (squeeze, simulated defecation). Paradoxical contraction of the puborectalis or failure of perineal descent on bearing down strongly suggests a defecatory disorder.[1][6]
| Test | Indication |
|---|---|
| Basic labs (CBC, TSH, calcium, glucose, creatinine) | Selected patients with short history, alarm features, or suspected metabolic cause |
| Colonoscopy | Alarm features, or due for age-appropriate colorectal cancer screening |
| Anorectal manometry + balloon expulsion test | Refractory constipation, suspicion for defecatory disorder, or pre-surgical assessment. Workflow and interpretation → see Defecatory Dysfunction |
| Colonic transit (radiopaque markers or scintigraphy) | Refractory constipation after excluding or treating an outlet disorder; guides subtype and surgical candidacy |
| Defecography (fluoroscopic or MR) | Suspected structural outlet obstruction — rectocele, intussusception, enterocele, perineal descent |
Management
Management proceeds in a stepwise fashion: lifestyle and fiber → osmotic laxatives → stimulants as rescue → prescription secretagogues and prokinetics for OTC failures → biofeedback for defecatory disorders → surgery in carefully selected refractory cases.[4][5]
Lifestyle and Dietary Measures
- Toileting routine — post-prandial attempts leveraging the gastrocolic response; knees-above-hips positioning (e.g., footstool); avoidance of prolonged straining.
- Hydration — adequate fluid intake, particularly with fiber.
- Physical activity — modest evidence for benefit; reasonable first-line adjunct.
Pharmacologic Therapy — AGA/ACG 2023 Recommendations
The 2023 AGA–ACG guideline on pharmacologic management of chronic idiopathic constipation provides the strongest current evidence synthesis.[4]
| Class | Agent | Recommendation | Certainty | Key Implementation Notes |
|---|---|---|---|---|
| Fiber | Psyllium | Conditional (suggest) | Low | First-line for patients with low dietary fiber intake; encourage hydration; flatulence is common; evidence for bran and inulin is very limited |
| Osmotic | PEG | Strong (recommend) | Moderate | Durable response at 6 months; well tolerated; combine with fiber as needed |
| Magnesium oxide | Conditional (suggest) | Very low | Start low, titrate; avoid in renal insufficiency (hypermagnesemia risk) | |
| Lactulose | Conditional (suggest) | Very low | Reserve for OTC failures; bloating and flatulence are dose-limiting | |
| Stimulant | Bisacodyl / sodium picosulfate | Strong (recommend) | Moderate | Short-term (≤4 wk) or rescue therapy; start low to limit cramping and diarrhea |
| Senna | Conditional (suggest) | Low | Trials used higher doses than are common in practice; start low and titrate | |
| Secretagogue | Lubiprostone | Conditional (suggest) | Low | For OTC failures; take with food and water to reduce nausea |
| Linaclotide | Strong (recommend) | Moderate | For OTC failures; diarrhea is the main adverse effect | |
| Plecanatide | Strong (recommend) | Moderate | For OTC failures; comparable efficacy and AE profile to linaclotide | |
| 5-HT4 agonist | Prucalopride | Strong (recommend) | Moderate | For OTC failures; headache, abdominal pain, nausea, diarrhea are the most common AEs |
A reasonable first-line regimen for most adults is fiber (psyllium) + PEG, with bisacodyl or sodium picosulfate reserved for rescue. Patients who fail or cannot tolerate OTC therapy should advance to a secretagogue (linaclotide, plecanatide, or lubiprostone) or the 5-HT4 agonist prucalopride; choice is driven largely by payer formulary, comorbidity (e.g., avoid magnesium oxide in CKD), and side-effect profile.[4]
Defecatory Disorders — handled separately
Patients with dyssynergia or inadequate propulsion confirmed on ARM + BET are treated with anorectal biofeedback as first-line — not further pharmacology escalation. The full diagnostic workflow and treatment algorithm (biofeedback, botulinum toxin, selected structural surgery) lives on the Defecatory Dysfunction page.[6][10]
The relevant point for constipation management: address the outlet before escalating laxatives/secretagogues. Slow-transit constipation commonly improves once evacuation is restored.[1][6]
Surgical Considerations
Surgery for chronic constipation is reserved for carefully selected refractory patients after exhaustive medical and pelvic floor therapy, and mandates objective physiologic confirmation of the constipation subtype.[5]
| Indication | Operation | Notes |
|---|---|---|
| Medically refractory slow-transit constipation; normal ARM/BET; no generalized GI dysmotility | Total abdominal colectomy with ileorectal anastomosis (TAC-IRA) | High symptom satisfaction but meaningful rates of persistent abdominal pain, bloating, small-bowel obstruction, and diarrhea; exclude upper GI dysmotility preoperatively |
| Symptomatic, reducible rectocele with trapping on defecography and splinting on history | Transvaginal / transanal / transperineal rectocele repair | Best outcomes when obstructed defecation is demonstrably mechanical and dyssynergia has been corrected |
| Symptomatic, high-grade rectal intussusception or external rectal prolapse | Ventral mesh rectopexy (or abdominal/perineal alternatives) | Concurrent sacrocolpopexy is frequently indicated when apical prolapse coexists |
| Enterocele / sigmoidocele contributing to obstructed defecation | Enterocele repair, often as part of apical suspension | Address concurrent apical defects |
Colectomy should not be offered for chronic constipation without documented slow transit, an excluded defecatory disorder (normal ARM/BET or corrected dyssynergia), and exclusion of generalized GI dysmotility. Outcomes of colectomy performed in unselected patients are poor.[5]
Outcomes and Follow-Up
- PEG produces durable response at 6 months in most patients; tachyphylaxis is uncommon.[4]
- Linaclotide and plecanatide achieve sustained CSBM response in 20–30% of patients, an absolute ~10–15% benefit over placebo.[4][8][9]
- Prucalopride demonstrates sustained efficacy over 12 weeks to 24 months with preserved cardiovascular safety in contemporary trials.[7]
- Biofeedback for dyssynergia produces symptom improvement in 70–80% of appropriately selected patients with response durable at ≥1 year.[6][10]
- Colectomy for STC — symptom satisfaction 70–90% in carefully selected series, but long-term morbidity (SBO, persistent abdominal pain, diarrhea) is substantial.[5]
Follow-up intervals are typically 4–8 weeks during initial titration and 3–6 months once a stable regimen is established. Patients on long-term laxatives should be reassessed periodically for efficacy and for the emergence of alarm features.
See Also
- Defecatory Dysfunction — physiologic workup, biofeedback, botulinum toxin
- Fecal Incontinence — including FI-mixed-with-constipation and overflow FI
- Defecatory Disorders — section landing
- Posterior Compartment Prolapse
- Anorectal Function & Defecography
References
1. Bharucha AE, Lacy BE. "Mechanisms, Evaluation, and Management of Chronic Constipation." Gastroenterology. 2020;158(5):1232-1249.e3. doi:10.1053/j.gastro.2019.12.034
2. Suares NC, Ford AC. "Prevalence of, and Risk Factors for, Chronic Idiopathic Constipation in the Community: Systematic Review and Meta-analysis." Am J Gastroenterol. 2011;106(9):1582-1591. doi:10.1038/ajg.2011.164
3. Lacy BE, Mearin F, Chang L, et al. "Bowel Disorders." Gastroenterology. 2016;150(6):1393-1407. doi:10.1053/j.gastro.2016.02.031
4. Chang L, Chey WD, Imdad A, et al. "American Gastroenterological Association–American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation." Gastroenterology. 2023;164(7):1086-1106. doi:10.1053/j.gastro.2023.03.214
5. The American Society of Colon and Rectal Surgeons. "Clinical Practice Guidelines for the Evaluation and Management of Chronic Constipation." Dis Colon Rectum. 2024;67(10):1244-1257. Link
6. Rao SSC, Bharucha AE, Chiarioni G, et al. "Anorectal Disorders." Gastroenterology. 2016;150(6):1430-1442. doi:10.1053/j.gastro.2016.02.009
7. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. "A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation." N Engl J Med. 2008;358(22):2344-2354. doi:10.1056/NEJMoa0800670
8. Lembo AJ, Schneier HA, Shiff SJ, et al. "Two randomized trials of linaclotide for chronic constipation." N Engl J Med. 2011;365(6):527-536. doi:10.1056/NEJMoa1010863
9. DeMicco M, Barrow L, Hickey B, et al. "Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation." Therap Adv Gastroenterol. 2017;10(11):837-851. doi:10.1177/1756283X17734697
10. Rao SS, Benninga MA, Bharucha AE, et al. "ANMS-ESNM position paper and consensus guidelines on biofeedback therapy for anorectal disorders." Neurogastroenterol Motil. 2015;27(5):594-609. doi:10.1111/nmo.12520